Pomegranate (Punica granatum L.) peel extract ameliorates metabolic syndrome risk factors in patients with non-alcoholic fatty liver disease: a randomized double-blind clinical trial.
Study Goal
The researchers aimed to evaluate the effects of pomegranate peel extract supplementation on hepatic status and metabolic syndrome risk factors in NAFLD patients.
Results Summary
The study found that 1500 mg of pomegranate peel extract, combined with a weight-loss diet, improved metabolic syndrome risk factors (e.g., reduced body weight, waist circumference, BMI) and decreased hepatic steatosis in NAFLD patients after 8 weeks.
Population
NAFLD patients (mean age 43.1 ± 8.6 years, 51.3% female).
Effective Dosage
1500 mg pomegranate peel capsules daily.
Duration
8 weeks.
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
pomegranate peel extract (PP) supplementation | improve | metabolic syndrome risk factors | patients with NAFLD | - | improved | #1 |
pomegranate peel extract (PP) supplementation | decrease | hepatic steatosis | patients with NAFLD | - | reduced | #2 |
pomegranate peel extract (PP) supplementation with a weight-loss diet | decrease | mean body weight | NAFLD patients | -5.10 ± 2.30 kg | changed | #3 |
pomegranate peel extract (PP) supplementation with a weight-loss diet | decrease | waist circumference | NAFLD patients | -7.57 ± 2.97 cm | changed | #4 |
pomegranate peel extract (PP) supplementation with a weight-loss diet | decrease | body mass index | NAFLD patients | -1.82 ± 0.85 kg/m² | changed | #5 |
INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is a metabolic syndrome (MS)-related liver disorder that has an increasing prevalence. Thus, the aim of our study is to evaluate the effects of pomegranate peel extract (PP) supplementation on hepatic status and metabolic syndrome risk factors. METHODS: In phase one, the hydro-alcoholic extraction of the peel of 750 kg of pomegranate (Punica granatum L.) was performed by the soaking method. Then, in phase two, NAFLD patients received 1500 mg of placebo (n = 37) or pomegranate peel capsules (n = 39) with a 500-kcal deficit diet for 8 weeks. Gastrointestinal intolerance, dietary intake, lipid and glycemic profiles, systolic and diastolic blood pressure, body composition, insulin resistance indexes, and elastography-evaluated NAFLD changes were followed. RESULTS: The mean age of participants was 43.1 ± 8.6 years (51.3% female). Following the intervention, the mean body weight (mean changes: -5.10 ± 2.30 kg), waist circumference (-7.57 ± 2.97 cm), body mass index (-1.82 ± 0.85 kg/m CONCLUSION: In conclusion, 1500 mg pomegranate peel extract along with a weight-loss diet improved metabolic syndrome risk factors and reduced hepatic steatosis in patients with NAFLD after 8 weeks.